Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Safety of in utero exposure to maternal IBD pharmacotherapies

Nature Reviews Gastroenterology & Hepatology volume 19, pages 213–214 (2022)Cite this article

Subjects

Although available clinical outcome data are reassuring, the consequences of in utero exposure to inflammatory bowel disease (IBD) pharmacotherapies on the development of the neonatal immune system remain ill-defined. So too does the converse effect on immunological maturation of fetal exposure to maternal inflammatory activity. Both warrant elucidation to appropriately stratify antenatal IBD care.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Competing risks of exposure to inflammation and immunomodulators in utero.

References

  1. Mahadevan, U. et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 160, 1131–1139 (2021).

    Article  CAS  Google Scholar 

  2. Sabic, D. & Koenig, J. M. A perfect storm: fetal inflammation and the developing immune system. Pediatr. Res. 87, 319–326 (2020).

    Article  Google Scholar 

  3. Estes, M. L. & McAllister, A. K. Maternal immune activation: implications for neuropsychiatric disorders. Science 353, 772–777 (2016).

    Article  CAS  Google Scholar 

  4. Esteve-Solé, A. et al. Immunological changes in blood of newborns exposed to anti-TNF-α during pregnancy. Front. Immunol. 8, 1123 (2017).

    Article  Google Scholar 

  5. Jennewein, M. F., Butler, A. L. & Alter, G. Neonate-omics: charting the unknown immune response in early life. Cell 174, 1051–1053 (2018).

    Article  CAS  Google Scholar 

  6. Kanis, S. L. et al. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut 70, 1266–1274 (2021).

    Article  Google Scholar 

  7. Jølving, L. R., Anru, P. L., Nielsen, J., Friedman, S. & Nørgård, B. M. The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines. Aliment. Pharmacol. Ther. 54, 1061–1069 (2021).

    Article  Google Scholar 

  8. Beaulieu, D. B. et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin. Gastroenterol. Hepatol. 16, 99–105 (2018).

    Article  Google Scholar 

  9. Kattah, M. G. et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin. Transl Gastroenterol. 9, 143 (2018).

    Article  Google Scholar 

  10. Schen, F. P. et al. Pregnancy in renal transplantation: immunologic evaluation of neonates from mothers with transplanted kidney. Transpl. Immunol. 9, 161–164 (2002).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

R.E.P. is funded by an Australian Government Research Training Program Scholarship. C.A.N.-P. is funded by an NHMRC Investigator Grant Leadership 1 (grant 1173584). The authors were also supported by the Victorian State Government Operational Infrastructure Scheme. M.F.N. is funded by the Fielding Fellowship 2017 by the Fielding Foundation.

Author information

Authors and Affiliations

  1. Gastroenterology Department, Monash Health, Melbourne, Victoria, Australia

    Ralley E. Prentice, Sally J. Bell & Rimma Goldberg

  2. School of Clinical Sciences, Department of Medicine, Monash University, Melbourne, Victoria, Australia

    Ralley E. Prentice, Sally J. Bell & Rimma Goldberg

  3. St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia

    Ralley E. Prentice

  4. Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia

    Ralley E. Prentice, Claudia A. Nold-Petry, Marcel F. Nold & Rimma Goldberg

  5. Department of Paediatrics, Monash University, Melbourne, Victoria, Australia

    Claudia A. Nold-Petry & Marcel F. Nold

  6. Monash Newborn, Monash Children’s Hospital, Melbourne, Victoria, Australia

    Marcel F. Nold

Authors
  1. Ralley E. Prentice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally J. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia A. Nold-Petry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcel F. Nold
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rimma Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rimma Goldberg.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prentice, R.E., Bell, S.J., Nold-Petry, C.A. et al. Safety of in utero exposure to maternal IBD pharmacotherapies. Nat Rev Gastroenterol Hepatol 19, 213–214 (2022). https://doi.org/10.1038/s41575-021-00572-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-021-00572-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing